Albumedix has signed research agreement with OUS and UiO on CIR research
In a press release, the pharmaceutical company Albumedix (Copenhagen, Denmark) has announced that it has signed a strategic research agreement with Oslo University Hospital and University of Oslo. The three organisations will work together to improve understanding of the interaction between bioengineered albumin variants and the neonatal Fc receptor (FcRn).
The research agreement is a result of a long collaboration between Albumedix and CIR scientists Jan Terje Andersen and Inger Sandlie.
The aim of this research agreement will be to establish an in-depth molecular, cellular and in vivo understanding on how FcRn acts as a key player in homeostatic regulation of albumin and albumin-based therapeutics using state-of-the-art technologies and animal models.
Read the full press release at the Albumedix website: Albumedix, Oslo University Hospital and University of Oslo establish strategic research collaboration